Effect Of High-dose Vitamin Research Articles

Effects of High-Dose Vitamin C on Liver Function, Systemic Inflammatory and Immune Responses in Patients with Severe Acute Pancreatitis

The objective of this study was to explore the impact of high-dose vitamin C on severe acute pancreatitis patients. This study involved 76 hospital patients from November 2022 to November 2023, divided into two groups: a high-dose group (44 patients) receiving 10 g of vitamin C daily and a routine-dose group (32 patients) receiving 1 g daily. The study evaluated treatment effects, liver function, inflammation levels, and blood T-lymphocyte subsets and complications. At 14 days, the high-dose group showed better overall treatment effects, lower levels of liver enzymes and inflammatory markers, and higher levels of T lymphocytes, with no significant difference in complications compared to the routine-dose group. The findings suggest that high-dose vitamin C effectively improves liver function, reduces inflammation, and boosts immunity in severe acute pancreatitis patients.

The effect of high-dose vitamin D supplementation and an exercise program to lose weight on some biochemical variables of overweight women

Background and Study Aim. In recent years, there has been a technological revolution and development in all fields, particularly the sports field. This has imposed on man a lifestyle characterized by comfort at the expense of a significant portion of his movement and activities. The problem of obesity has expanded beyond the inconsistency of the body to include its direct effect of increasing the proportion of fat and the negative impact on the work of vital organs. This disruption alters the body's internal environment and causes numerous diseases. The purpose of this study is to determine the effect of a sports program on taking vitamin D to lose weight and on some biochemical variables in young adults aged 30 to 35 years old. Materials and Methods. The study involved 10 overweight women aged 30-35 years, selected through intentional sampling. Inclusion criteria required consent, good health, and no ongoing vitamin D or exercise programs. The research employed a Randomized Controlled Trial (RCT) design. Primary outcome measures encompassed body weight, body composition, lipid profile, and vitamin D status. Anthropometric measurements included age, height, weight, and training age. Biochemical measurements involved blood tests for cholesterol, triglycerides, and vitamin D levels. The experimental group received vitamin D tablets and a proposed aerobic exercise program for 12 weeks. Results. The proposed aerobic sports program with vitamin D intake improved biochemical variables, such as total fat, total cholesterol, triglyceride, high-density cholesterol, low-density cholesterol, OH, and Vitamin D-025 for the sample under investigation. The application of the aerobic program with vitamin D led to weight loss among the study's female participants. The aerobic program with vitamin D intake has a positive effect on the general health status of the sample. Conclusions. Based on the study's findings, it is recommended to consider the positive effects of Vitamin D on the overall functional state of the body, making it essential to incorporate an aerobic sports program across various age groups. Regular medical tests are crucial for monitoring and maintaining overall health. Emphasizing the importance of regular exercise is vital in preventing weight gain and reducing the risk of certain chronic diseases. By implementing these recommendations, individuals can enhance their overall well-being and lead a healthier lifestyle. To further validate these outcomes, similar studies should be conducted on different age groups and diverse samples.

Effect of High-dose Vitamin D on IL-1β Blood Level in Patients with Moderate Stroke: A Randomized Clinical Trial.

Vitamin D has neuroprotective and anti-inflammatory effects in stroke patients, but its effect on pro-inflammatory and inflammatory cytokines, especially IL-1, has been investigated in a few trials. This study aimed to determine the effect of prescribing a high dose of vitamin D on the anti-inflammatory parameters, short-term and long-term prognosis of patients with ischemic stroke. This randomized clinical trial was performed on 42 patients randomly divided into two equal groups of 21 in Imam Hussein Hospital. The patients were allocated through block randomization methods to receive 300,000 units of vitamin D (intramuscularly) or not receive it as a control group. Age, gender, and clinical and laboratory information were recorded. The stroke severity was calculated according to the National Institute of Health Stroke Scale (NIHSS) at the beginning of hospitalization and upon hospital discharge. The 3-month prognosis of the patients was recorded according to the Barthel criteria three months after the stroke. Vitamin D3 levels were recorded before and after injection, while the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were assessed on the first day and for 7 consecutive days after hospitalization. All statistical analyses were performed using STATA version 14. A P-value < 0.05 was considered significant. The mean age of the patients was 61.45 ± 4.74 years. There were 18 female (42.86%) and 24 male patients (57.14%). In the vitamin D group, the mean IL-1 decreased compared to before the intervention (-23.60 ± 103.83), but this decrease was not statistically significant (P = 0.070). In addition, the changes in IL-1 after the intervention were statistically different between the two groups (mean difference of -23.60 ± 103.83 in the vitamin D group vs. 15.96 ± 9.64 in the control group). The mean IL-6 decreased in both groups after the intervention compared to before, although these changes were not statistically significant (P > 0.05). In the group receiving vitamin D compared to the control group, the mean NLR decreased by about 2 units, the PLR decreased by about 10 units, and the NIHSS score decreased by about one unit during the study. However, these changes were not statistically significant (P > 0.05). A high dose of vitamin D can improve the NIHSS score and decrease IL-1 and IL-6, although these changes were not statistically significant. The mean NLR and PLR decreased after using high-dose vitamin D.

Effect of high-dose vitamin C and E supplementation on muscle recovery and training adaptation: a mini review.

This review aimed to investigate the effects of high-dose vitamins C and E supplementation combined with acute or chronic exercise on muscle recovery and training adaptation. We used PubMed, Web of Science, and Wiley Online Library databases to perform a literature search based on the keywords 'vitamin C, vitamin E, antioxidants, muscle recovery, training adaptation, and oxidative stress'. Vitamin C or E supplementation has been reported to contribute to a reduction in oxidative stress and muscle damage; however, there is currently inadequate evidence of their positive effects on muscle recovery. Long-term vitamin C or E supplementation can have negative effects on physiological phenomena required for training adaptation, such as strength, muscle hypertrophy, and endurance. Numerous studies emphasized that an adequate diet consisting of fruits and vegetables is a more appropriate way of consuming antioxidants than supplementation. The effects of high-dose vitamin C and E supplementation on post-exercise muscle recovery remain unclear and ambiguous, although there is evidence of potential negative effects on training adaptation.

No effects of high-dose vitamin D supplementation on white blood cell count, CRP and risk of upper respiratory tract infections in infertile men - Secondary analyses from a randomized clinical trial

Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Study of the Effect of High Dose Vitamin D on the Improvement of Bacterial Vaginosis in Vitamin D Deficient Women

Background: The current evaluation was planned to study the effect of vitamin D on improving bacterial vaginosis in premenopausal women with vitamin D deficiency.&#x0D; Methods: This study was an open-label clinical trial. Forty premenopausal vitamin D deficient women with bacterial vaginosis enrolled in this study. Patients received metronidazole tablet 500 mg twice daily for seven days in both groups. In the vitamin D group, patients also received 50000 IU per day for five days.&#x0D; Results: Fourteen days after completion of the study, the number of patients complaining of malodor vaginal discharge, vaginal itching, and discharge discoloration was significantly lower than that in the control group. Regarding the laboratory results, in the vitamin D group, the numbers of Gardnerella vaginalis, gram-negative bacilli, and clue cells in the smear of vaginal secretions were significantly less than in the control group (p&lt;0.05). Furthermore, none of the patients had a positive whiff test after treatment in the vitamin D group (p&lt;0.05). Fourteen days after the completion of the study, the plasma level of 25-OH vitamin D in the vitamin D group was significantly higher than that in the control group. However, the short course of high-dose vitamin D therapy did not increase the plasma concentration of 25-OH vitamin D to the average level.&#x0D; Conclusion: Vitamin D supplementation can improve the therapeutic response to metronidazole in vitamin D deficient women with BV. However, large-scale double-blind, randomized clinical trials must confirm this finding.

The effect of high-dose vitamin D supplementation on hepcidin-25 and erythropoiesis in patients with chronic kidney disease

BackgroundHepcidin is considered to play a central role in the pathophysiology of renal anemia. Recent studies in healthy individuals have demonstrated a suppressive effect of vitamin D (VD) on the expression of hepcidin. In this post-hoc analysis based on a randomized controlled study, we evaluated the effect of supplementing chronic kidney disease (CKD) patients (stage G3-G4) with a high daily dose of native VD on serum levels of hepcidin-25, the hepcidin/ferritin ratio, as well as on markers of erythropoiesis.MethodsPatients with CKD stage G3-G4 included in a double blind, randomized, placebo (PBO) controlled study with available hepcidin measurements were analyzed. Study subjects received either 8000 international units (IU) of cholecalciferol daily or PBO for 12 weeks. We evaluated the change in markers of hepcidin expression, erythropoiesis, and iron status from baseline to week 12 and compared the change between the groups.ResultsEighty five patients completed the study. Calcitriol, but not 25-hydroxyvitamin D (25(OH) D), was inversely correlated with serum levels of hepcidin-25 (rho = -0,38; p = < 0, 01 and rho = -0,02; p = 0, 89, respectively) at baseline. Supplementation with VD significantly raised the serum concentration of serum 25(OH)D in the treatment group (from 54 (39–71) to 156 (120–190) nmol/L; p = < 0, 01)) but had no effect on any of the markers of hepcidin, erythropoiesis, or iron status in the entire cohort. However, we did observe an increase in hemoglobin (HB) levels and transferrin saturation (TSAT) as compared to the PBO group in a subgroup of patients with low baseline 25(OH)D levels (< 56 nmol/L). In contrast, in patients with high baseline 25(OH)D values (≥ 56 nmol/L), VD supplementation associated with a decrease in HB levels and TSAT (p = 0,056) within the VD group in addition to a decrease in hepcidin levels as compared to the PBO group.ConclusionHigh-dose VD supplementation had no discernible effect on markers of hepcidin or erythropoiesis in the entire study cohort. However, in patients with low baseline 25(OH)D levels, high-dose VD supplementation associated with beneficial effects on erythropoiesis and iron availability. In contrast, in patients with elevated baseline 25(OH)D levels, high-dose VD supplementation resulted in a decrease in hepcidin levels, most likely due to a deterioration in iron status.

Vitamin D supplementation and adverse skeletal and non-skeletal outcomes in individuals at increased cardiovascular risk: Results from the International Polycap Study (TIPS)-3 randomized controlled trial

Background and aimsVitamin D has mostly been tested in Western populations. We examined the effect of high dose vitamin D in a population drawn predominantly from outside of Western countries. Methods and resultsThis randomized trial tested vitamin D 60,000 IU monthly in 5670 participants without vascular disease but at increased CV risk. The primary outcome was fracture. The secondary outcome was the composite of CV death, myocardial infarction stroke, cancer, fracture or fall. Death was a pre-specified outcome. Mean age was 63.9 years, and 3005 (53.0%) were female. 3034 (53.5%) participants resided in South Asia, 1904 (33.6%) in South East Asia, 480 (8.5%) in South America, and 252 (4.4%) in other regions. Mean follow-up was 4.6 years. A fracture occurred in 20 participants (0.2 per 100 person years) assigned to vitamin D, and 19 (0.1 per 100 person years) assigned to placebo (HR 1.06, 95% CI 0.57–1.99, p-value = 0.86). The secondary outcome occurred in 222 participants (1.8 per 100 person years) assigned to vitamin D, and 198 (1.6 per 100 person years) assigned to placebo (HR 1.13, 95% CI 0.93–1.37, p = 0.22). 172 (1.3 per 100 person years) participants assigned to vitamin D died, compared with 135 (1.0 per 100 person years) assigned to placebo (HR 1.29, 95% CI 1.03–1.61, p = 0.03). ConclusionIn a population predominantly from South Asia, South East Asia and South America, high-dose vitamin D did not reduce adverse skeletal or non-skeletal outcomes. Higher mortality was observed in the vitamin D group. Registration numberNCT01646437.

The effect of high-dose vitamin C on renal functions in COVID–19 patients

Background: With its important properties, Vitamin C has been used in several diseases and sepsis. COVID-19 may cause sepsis, and therefore high dose Vitamin C has been integrated to the treatment protocols.Concerning the potential risk of oxalate nephropaty related with the use of long term or high dose Vitamin C, we retrospectively evaluated the COVID-19 patients treated with the high dose intravenous Vitamin C, in terms of kidney dysfunction. Material and Method: Critically ill COVID-19 patients who were given Vitamin C 45-50 gr/day/5 days (Group C, n=21), and the ones who did not (Group NC, n=22) along with the hydroxychloroquine- favipiravir treatment were compared in terms of developing renal dysfunction within the 15 days of ICU stay. Results: There were no difference in the development of renal dysfunction between the groups with and without Vitamin C treatment (p&gt;0.05). But when the patients who had KDIGO stage 1 kidney damage on admission, and had worsening renal dysfunction during ICU stay were excluded, patients groups were more similar and the development of the renal failure was significantly more in Vitamin C group(p&lt;0.05). Conclusion: We conclude that when administering high dose parenteral Vitamin C, kidney functions should be carefully assessed.

30 EFFECT OF HIGH-DOSE VITAMIN D ON HYPERTENSION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Background: Vitamin D deficiency has been linked with the risk of developing hypertension. Every 16 ng/mL decrease in vitamin D increase the risk of hypertension by 16%. Studies of standard vitamin D supplementation have not provided beneficial effect in lowering blood pressure in patients with hypertension. This study aims to determine the effect of high dose vitamin D supplementation in lowering blood pressure in hypertensive patient compared to placebo. Method: Systematic literatures search was conducted through online databases including PubMed and the Cochrane Library to find relevant randomized controlled trials (RCTs) from January 2010 to December 2021. Random-effect model was used to pool the weighted mean difference (WMD) of blood pressure across studies. Confidence Interval (CI) of 95% were reported. I2 test was used to assess the heterogeneity across studies. Meta-analysis was performed using RevMan 5.3. Result: Four RCTs involving 1100 participants were included. On pooled analysis, high dose vitamin D supplementation did not show significant reduction in systolic blood pressure compared to placebo (WMD, 0.37; 95% CI, - 1.34 to 2.09; p= 0.67). Similar finding was also found in the association of high dose vitamin D supplementation and diastolic blood pressure (WMD, 0.32;95% CI, - 0.80 to 1.45; p= 0.57). Conclusion: High dose vitamin D supplementation does not lower systolic and diastolic blood pressure in hypertensive patients

Effect of high dose vitamin D supplementation on indices of sarcopenia and obesity assessed by DXA among older adults: A randomized controlled trial.

Hypovitaminosis D is associated with Sarcopenic Obesity (SO), but evidence from randomized Vitamin D 3 (VD3) trials is scarce. Compare the effect of VD3 supplementation, at two doses, on SO indices at 12 months. Overweight older adults (>65 years) with baseline 25-hydroxyvitamin D (25OHD) of 10-30 ng/mL were recruited in this double-blind, randomized, controlled multicenter trial (clinicaltrial.gov identifier: NCT01315366). All subjects received 1000 mg calcium citrate/day and underwent total body Dual-energy X-ray Absorptiometry for body composition assessment. Low Dose Group (LDG) and High Dose Group (HDG) received 600 IU -Institute of Medicine (IOM) Recommended Dietary Allowance (RDA)- and 3750 IU VD3/day, respectively. Mean age was 71 ± 4.6 years, 55% females, BMI: 30.2 ± 4.5 Kg/m2, and 43% had metabolic syndrome. There were no differences in baseline characteristics between groups. At 12 months, 248 participants had body composition data, 122 in LDG and 126 in HDG. Proportions of patients with diminished muscle mass, muscle strength, and visceral adiposity did not differ between the 2 groups at baseline or 12 months. Similarly, no significant differences were noted in the proportion of patients with SO at study entry (1.8% in LDG vs 1.6% HDG; p = 0.99) and at 12 months (3.7% in LDG vs. 0.9% HDG; p = 0.18) across arms. Weekly VD3, at the daily equivalent of 3750 IU/day, did not improve indices of sarcopenia nor adiposity compared to the IOM RDA dose in adults.

The effect of High-Dose Vitamin C Treatment for Acute Respiratory Failure Due to Coronavirus Disease Pneumonia on Mortality and Length of Intensive Care Stay: A Retrospective Cohort Study.

In our study, we aimed to determine the effect of vitamin C on short-term mortality and length of intensive care unit (ICU) stay in patients with coronavirus disease (COVID-19) followed up in the ICU. The patients who received and those who did not receive the high-dose intravenous vitamin C protocol were assigned to the treatment and control groups, respectively. The primary study findings in both groups were length of ICU stay and short-term mortality, while the secondary findings were vasopressor and invasive mechanical ventilation requirements and change in sequential organ failure assessment score from the 0 to the 96th hour. Thirty-eight patients were included in the treatment group and 40 were included in the control group. The mortality rates were 44% and 60% in the treatment and control groups, respectively; however, the difference between the groups was not statistically significant (p>0.05). The median length of ICU stay in both groups was 10 days (p>0.05). No significant differences in the invasive mechanical ventilation and vasopressor requirements were found between the groups (p>0.05). Consequently, the high-dose vitamin C therapy in the patients with acute respiratory failure due to COVID-19 pneumonia did not reduce the length of ICU stay, mortality, and invasive mechanical ventilation and vasopressor reqirements.

The Effect of High Dose Vitamin C (ascorbic acid) on Proinflammatory Cytokines in COVID-19

Background: COVID-19 is a new pandemic that has claimed many lives in many countries. This pandemic was caused by the SARSCoV2. Until now, there is no specific antiviral drug or vaccine against Covid-19 for potential therapy in humans. This virus can cause cytokine storms which can worsen symptoms in sufferers due to an imbalance between increased oxidant production and available antioxidants. Vitamin C is an important antioxidant that protects the body from various bad effects of free radicals. At high concentrations vitamin C plays an important role in immunomodulation. This study was conducted to determine the effect of high doses of vitamin C on levels of pro-inflammatory cytokines in Covid-19. Method: This research type is literature study. The population in this study were journals about Covid-19, vitamin C, antioxidants and free radicals, inflammatory reactions due to viral infections with samples taken from indexed journals published from 2015 to 2020. There are also clinical trials of high doses of vitamin C against inflammation in Covid-19 from these journals. Results: The results of the study in a clinical trial conducted on 54 patients enrolled in 3 hospitals given a 1: 1 ratio for high-dose intravenous vitamin C (HDIVC) or placebo administration. The HDIVC group received 12 g of vitamin C / 50 ml every 12 hours for 7 days at a rate of 12 ml / hour, and the placebo group received bacteriostatic water for injection in the same way. HDIVC administration showed a reduction in inflammatory markers compared to placebo. Conclusion: The conclusion of this study shows that high doses of vitamin C play a role in reducing levels of proinflammatory cytokines.

Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial

BackgroundVitamin C is an essential water-soluble nutrient that functions as a key antioxidant and has been proven to be effective for boosting immunity. In this study, we aimed to assess the efficacy of adding high-dose intravenous vitamin C (HDIVC) to the regimens for patients with severe COVID-19 disease.MethodsAn open-label, randomized, and controlled trial was conducted on patients with severe COVID-19 infection. The case and control treatment groups each consisted of 30 patients. The control group received lopinavir/ritonavir and hydroxychloroquine and the case group received HDIVC (6 g daily) added to the same regimen.ResultsThere were no statistically significant differences between two groups with respect to age and gender, laboratory results, and underlying diseases. The mean body temperature was significantly lower in the case group on the 3rd day of hospitalization (p = 0.001). Peripheral capillary oxygen saturations (SpO2) measured at the 3rd day of hospitalization was also higher in the case group receiving HDIVC (p = 0.014). The median length of hospitalization in the case group was significantly longer than the control group (8.5 days vs. 6.5 days) (p = 0.028). There was no significant difference in SpO2 levels at discharge time, the length of intensive care unit (ICU) stay, and mortality between the two groups.ConclusionsWe did not find significantly better outcomes in the group who were treated with HDIVC in addition to the main treatment regimen at discharge.Trial registration irct.ir (IRCT20200411047025N1), April 14, 2020

Effects of high dose vitamin C administration in Covid-19 patients

Aim: There is currently no pharmacotherapy with for the treatment of COVID-19. We aimed to investigate the effects of early and high-dose vitamin C (VC) therapy in hospitalized patients with COVID-19.Materials and Methods: We included patients (n=139) who received high-dose VC supplement to the standard treatment protocol into group 1 (n=58), and only those who received a standard treatment protocol into group 2 (n=81). The patients' requirement for supplemental oxygen therapy, requirement for intensive care treatment and survival rates was investigated retrospectively. Furthermore, the changes in white blood cell, C-reactive protein (CRP), procalcitonin, D-Dimer, renal function tests, ferritin, and interleukin 6 values during hospitalization were evaluated.Results: When the groups were compared in terms of clinical data, there was no significant difference in terms of the patients requiring supplemental oxygen therapy (p=0.808), requiring intensive care (p=0.662), and survival rates (p=0.185). However, a significant difference was observed between the groups in terms of changes in renal function tests, and CRP values (p<0.05).Conclusion: In the present study, early administration of high-dose VC to patients with COVID-19 has a reducing effect on the impaired kidney functions. Therefore, we recommend the use of VC as an early supplemental therapy in patients with COVID-19.

Reducing the Side-Effects of Cisplatin to Improve the Social Acceptance of Chemotherapy as CAM Adjunct in Cancer Treatment

Background: In sociology, the prevalence of cancer is interpreted as a broken social contract that requires behaviour change. Complementary and alternative medicine (CAM) is a vital social phenomenon, whose usage is socially patterned out. Perceptions of the limitations of chemotherapy and radiotherapy among cancer patients have contributed to the preference for CAM use, particularly plant-derived polysaccharides like HemoHIM, which contain cisplatin. This research was undertaken to show whether co-administration of vitamin C with cisplatin in chemotherapy can prevent or reduce the side-effects of cisplatin nephrotoxicity. Objectives: The objective of this study was to overturn social perceptions of conventional therapy as associated with nephrotoxicity. It investigates the renoprotective effects of high-dose vitamin C by performing an animal experiment to determine body weight, organ weight, and biochemical blood parameters; as well as to measure inflammatory cytokines. Design: Mice were randomly divided into five groups (control; and 500, 1000, and 2000 mg/kg of vitamin C with cisplatin). All groups except for the control group were intraperitoneally injected with 5- mg/kg cisplatin for 10 days, and the mice in the respective groups were orally administered each 500-, 1000-, 2000- mg/kg vitamin C 2 h prior to cisplatin treatment. After 10 days, the mice were sacrificed, and their blood samples and kidney tissues were obtainedfor further analysis. Setting and location: Republic of Korea Methods: Blood samples from animal experiments and tissue preparation were analyzed using real-time quantitative polymerase chain reaction. Results: The intraperitoneal injection of cisplatinreduced body weight, and elevated levels of blood urea nitrogen, serum creatinine, and uric acid. It also triggered an inflammatory response in the mouse kidney by inducing the pro-inflammatory cytokines TNFα, IL-6, and IL-1β and increasing in the expression of iNOS, and IL-4. Renal injury was decreased by the administration of vitamin C; the oral administration of vitamin C (500, 1000, 2000 mg/kg) decreased or normalized the renal function through the attenuation of cisplatin-induced inflammatory cytokines and the modulation of biochemical parameters (ALT, AST, cholesterol, TG, HDL, LDL, blood urea nitrogen, creatinine, and Uric acid) following the intraperitoneal injection of cisplatin. Conclusion: The results of our present study suggest that the co-administration of vitamin C with cisplatin chemotherapy is a promising method to prevent or reduce the side effects of cisplatin nephrotoxicity. These findings can remodel how the Korean society thinks, approaches and fights cancer by showing how nephrotoxicity can be counteracted to ensure social acceptance of CAM as an adjunctive to cisplatin therapy. Keywords: Complementary and alternative medicine, CAM, Vitamin C, Renoprotective therapy, Cisplatin, Nephrotoxicity, High-dose vitamin C DOI: 10.7176/JHMN/81-11 Publication date: October 31 st 2020

Effects of High-Dose Vitamin D Supplementation on Phase Angle and Physical Function in Patients with Prostate Cancer on ADT

Purpose Androgen deprivation therapy (ADT) is commonly used to treat patients with advanced prostate cancer but is associated with functional decline. Bioelectrical impedance analysis (BIA)-derived phase angle may reflect frailty and functional decline in cancer patients. High-dose vitamin D supplementation may improve phase angle values and physical function. Methods We conducted an exploratory analysis from a phase II randomized controlled trial investigating the efficacy of high-dose vitamin D supplementation in prostate cancer patients (age ≥ 60 yrs). Fifty-nine patients were randomized to high-dose vitamin D (600 IU/day plus 50,000 IU/week) or low-dose: RDA for vitamin D (600 IU/day plus placebo weekly) for 24 weeks. Phase angle was measured by BIA. Physical function measures included handgrip strength, 6-minute walk test, Short Performance Physical Battery and leg extension. All testing was completed at baseline, week 12 and week 24. Results Phase angle values were wider over the entire study in the high-dose vitamin D arm indicating healthier muscle cells. The low-dose vitamin D arm had phase angle values consistent with frailty cutoffs in older men (<5.7°). Conclusion Patients in the high-dose vitamin D arm experienced wider phase angle values over the course of the study which may indicate less frailty. ClinicalTrials.gov ID: NCT02064946.

Effect of high-dose vitamin D supplementation on peripheral arterial calcification: secondary analysis of a randomized controlled trial.

To determine whether vitamin D supplementation has a dose-dependent effect on development and progression of arterial calcification. This was a secondary analysis of the Calgary Vitamin D Study, a 3-year, double-blind, randomized controlled trial conducted at a single-center in Calgary, Canada. Participants were community-dwelling adults aged 55-70years with serum 25-hydroxyvitamin D 30-125nmol/L. Participants were randomized 1:1:1 to receive vitamin D3 400, 4000, or 10,000IU/day for 3years. Tibial artery calcification was identified and quantified (in milligrams of hydroxyapatite, mgHA) using high-resolution peripheral quantitative computed tomography (HR-pQCT) at baseline and 6, 12, 24, and 36months. Changes in calcification over time and treatment group interaction were evaluated using a constrained linear mixed effects model. Of 311 randomized participants, 302 (400: 105, 4000: 96, 10,000: 101) were eligible for analysis of arterial calcification (54% male, mean (SD) age 62 (4) years, mean (SD) 25-hydroxyvitamin D 78.9 (19.9) nmol/L). At baseline, 85 (28%) had tibial artery calcification, and mean (95% CI) calcification quantity was 2.8mgHA (95% CI 1.7-3.9). In these 85 participants, calcification quantity increased linearly by 0.020mgHA/month (95% CI 0.012-0.029) throughout the study, with no evidence of a treatment-group effect (p = 0.645 for interaction). No participants developed new arterial calcifications during the study. In this population of community-dwelling adults who were vitamin D replete at baseline, supplementation with vitamin D 400, 4000, or 10,000IU/day did not have differential effects on the development or progression of arterial calcification over 3years. clinicaltrials.gov (NCT01900860).

Effect of High Dose Vitamin C on Proliferation and Apoptosis of Acute Myeloid Leukemia Cells

To investigate the effects of high dose vitamin C on proliferation and apoptosis of acute myeloid leukemia (AML) cell lines including HL-60, U937 and primary CD34+ leukemia cells in AML. CD34+ cells were sorted by using immunomagnetic cell sorting system, then the primary CD34+ leukemia cells, including HL-60 and U937 cell lines were cultured in vitro. Cells in each group were treated with different concentrations of vitamin C, the survival rate of cells was determined by MTT assay, the apoptosis rate of cells was evaluated by Annexin V/PI double staining, the expression of apoptotic proteins-including cleaved caspase 3, cleaved caspase-9 and cleaved PARP were detected by Western blot. The proliferation of HL-60 and U937 cells could be inhibited by high dose vitamin C, which showed a concentration-dependent manner (r=-0.9664; r=-0.9796). HL-60 and U937 cells were treated with different concentrations of vitamin C (8 and 20 mmol/L) for 24 hours, respectively, it was found that with the increasing of vitamin C concentration, cell apoptosis rate was significantly increased (r=0.9905; r=0.9971), and the expression of apoptosis related proteins including cleaved caspase 3, cleaved caspase-9 and cleaved PARP was aslo significantly increased with the increasing of concentration. In addition, it was found that with or without the mutation of TET2, high dose vitamin C could inhibit the proliferation (r=-0.9719; r=-0.9699) and promote the apoptosis (r=0.9998; r=0.9901) of primary CD34+ leukemia cells in AML, which showed a dose-dependent manner, but it showed no effect on the proliferation (r=-0.2032) and apoptosis (r=0.1912) of normal CD34+ cells. High dose vitamin C can inhibit the proliferation and promote the apoptosis of acute myeloid leukemia cells, and selectively kill primary CD34+ leukemia cells in AML.

Back to the Drawing Board? Effects of High-Dose Vitamin D Supplementation in Graves' Disease on Muscle Strength, Lean Mass Gain, and Quality of Life.

Back to the Drawing Board? Effects of High-Dose Vitamin D Supplementation in Graves' Disease on Muscle Strength, Lean Mass Gain, and Quality of Life.